Jounce Therapeutics, Inc. Common Stock
JNCE
JNCE was delisted on the 3rd of May, 2023.
80 hedge funds and large institutions have $122M invested in Jounce Therapeutics, Inc. Common Stock in 2019 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 27 increasing their positions, 31 reducing their positions, and 5 closing their positions.
178% more call options, than puts
Call options by funds: $161K | Put options by funds: $58K
40% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 5
0% more funds holding
Funds holding: 80 → 80 (0)
13% less repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 31
21% less capital invested
Capital invested by funds: $153M → $122M (-$31.8M)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1M |
| 2 |
N
Nuveen
Charlotte,
North Carolina
|
+$744K |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
+$697K |
| 4 |
State Street
Boston,
Massachusetts
|
+$638K |
| 5 |
SO
STRS Ohio
Columbus,
Ohio
|
+$505K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SIM
Spark Investment Management
New York
|
-$1.23M |
| 2 |
Two Sigma Investments
New York
|
-$532K |
| 3 |
AQR Capital Management
Greenwich,
Connecticut
|
-$524K |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$464K |
| 5 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$376K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
IUHSA
76
Itau Unibanco Holding S.A.
Sao Paulo,
Brazil
| $2K | -$2.45K | -461 | -55% |
|
|
LTFS
77
Ladenburg Thalmann Financial Services
Miami,
Florida
| $1K | – | – | – |
|
|
PCP
78
Proficio Capital Partners
Newton,
Massachusetts
| $1K | – | – | – |
|
79
Royal Bank of Canada
Toronto,
Ontario, Canada
| $1K | – | – | – |
|
80
Simplex Trading
Chicago,
Illinois
| $1K | +$1.24K | +234 | New |
|
81
Creative Planning
Overland Park,
Kansas
| – | -$371K | -59,789 | Closed |
|
82
Parallax Volatility Advisers
San Francisco,
California
| – | -$63K | -10,200 | Closed |
|
|
TCM
83
Tekla Capital Management
Boston,
Massachusetts
| – | -$63K | -10,127 | Closed |
|
84
Canada Pension Plan Investment Board
Toronto Ontario,
Ontario, Canada
| – | -$60K | -9,600 | Closed |
|
|
OWD
85
Osborn Williams & Donohoe
Cincinnati,
Ohio
| – | -$17K | -2,800 | Closed |
|
JNCE Hedge Fund Activity: Q2 2019 in Review
80 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Jounce Therapeutics, Inc. Common Stock (JNCE) for Q2 2019, worth a combined $122M — down 21% from $153M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new JNCE positions and 5 closed out — a net gain of 2 holders — while 27 added to existing stakes and 31 trimmed.
The largest buyer was Vanguard Group, adding an estimated $1M. The largest seller was Spark Investment Management, cutting an estimated $1.23M.
- 80 institutional investors held Jounce Therapeutics, Inc. Common Stock (JNCE) as of Q2 2019, unchanged from Q1 2019.
- Funds reported $122M of Jounce Therapeutics, Inc. Common Stock stock for Q2 2019, down 21% quarter-over-quarter.
- 7 funds opened new Jounce Therapeutics, Inc. Common Stock positions in Q2 2019 and 5 closed out, a net change of +2 holders.
- The largest Jounce Therapeutics, Inc. Common Stock buyer in Q2 2019 was Vanguard Group, an estimated $1M added.
- The largest Jounce Therapeutics, Inc. Common Stock seller in Q2 2019 was Spark Investment Management, an estimated $1.23M sold.
Based on aggregated 13F filings for Q2 2019.